Imagen de Portada

The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study

Guardado en:
Publicado en:NPJ Breast Cancer vol. 11, no. 1 (2025), p. 96-104
Autor principal: Brantley, Kristen D.
Otros Autores: Kirkner, Gregory J., Hughes, Melissa E., Varella, Leticia, Suggs, Georgia, Cunningham, Olivia M., Ravikumar, Sanjana, Snow, Craig, Tolaney, Sara M., Sammons, Sarah, Partridge, Ann H., Lin, Nancy U.
Publicado:
Nature Publishing Group
Materias:
Patients
Womens health
Epidermal growth factor
Histology
Metastasis
Age
Kinases
Radiation
Cyclin-dependent kinases
Breast cancer
Acceso en línea:Citation/Abstract
Full Text
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:The influence of young age at diagnosis on prognosis of patients with metastatic breast cancer (MBC) remains unclear. We examined overall survival (OS) within a single-institution prospective study of patients with de novo or recurrent MBC. Kaplan-Meier curves assessed OS by age (≤35 or ≤40 years as the youngest category) and inferred metastatic tumor subtype. Multivariable Cox regression models estimated hazard ratios (HRs) and 95% CIs for OS by age adjusting for clinical factors. Of 4189 women <75 years, 571 were ≤40 years at MBC diagnosis, of whom 260 were ≤35 years. Over half (52%) died during follow-up (median = 5.3 years, IQR = 2.1–9.8 years). Compared to patients 45–55 years, those ≤35 years at diagnosis experienced worse OS (HR = 1.22, 95%CI 1.00–1.48, p = 0.05). This association was driven by HER2-negative/luminal B-like and hormone receptor-positive/HER2-positive tumors. These findings highlight the need to develop more effective therapies for young patients with this metastatic subtype.
ISSN:2374-4677
DOI:10.1038/s41523-025-00822-y
Fuente:Health & Medical Collection